170 related articles for article (PubMed ID: 33093566)
1. Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses.
Bonar MM; Tabler CO; Haqqani AA; Lapointe LE; Galiatsos JA; Joussef-Piña S; Quiñones-Mateu ME; Tilton JC
Sci Rep; 2020 Oct; 10(1):18101. PubMed ID: 33093566
[TBL] [Abstract][Full Text] [Related]
2. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
Henderson GJ; Lee SK; Irlbeck DM; Harris J; Kline M; Pollom E; Parkin N; Swanstrom R
Antimicrob Agents Chemother; 2012 Feb; 56(2):623-33. PubMed ID: 22083488
[TBL] [Abstract][Full Text] [Related]
3. Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region.
Tabler CO; Wegman SJ; Alhusaini N; Lee NF; Tilton JC
Viruses; 2024 May; 16(6):. PubMed ID: 38932142
[TBL] [Abstract][Full Text] [Related]
4. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.
Tabler CO; Wegman SJ; Chen J; Shroff H; Alhusaini N; Tilton JC
J Virol; 2022 May; 96(9):e0219821. PubMed ID: 35438536
[TBL] [Abstract][Full Text] [Related]
6. Recent developments of peptidomimetic HIV-1 protease inhibitors.
Qiu X; Liu ZP
Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
8. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
9. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
Katzenstein D; Ogden R
Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
[No Abstract] [Full Text] [Related]
10. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year.
Bi X; Gatanaga H; Ida S; Tsuchiya K; Matsuoka-Aizawa S; Kimura S; Oka S
J Acquir Immune Defic Syndr; 2003 Sep; 34(1):1-6. PubMed ID: 14501787
[TBL] [Abstract][Full Text] [Related]
11. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
Condra JH; Holder DJ; Schleif WA; Blahy OM; Danovich RM; Gabryelski LJ; Graham DJ; Laird D; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M; Yang T; Chodakewitz JA; Deutsch PJ; Leavitt RY; Massari FE; Mellors JW; Squires KE; Steigbigel RT; Teppler H; Emini EA
J Virol; 1996 Dec; 70(12):8270-6. PubMed ID: 8970946
[TBL] [Abstract][Full Text] [Related]
12. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
Capel E; Martrus G; Parera M; Clotet B; Martínez MA
J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
[TBL] [Abstract][Full Text] [Related]
14. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
Yu M; Kabat W; Wang J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
[TBL] [Abstract][Full Text] [Related]
15. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
16. Sequence variability of the HIV type 1 protease gene in thai patients experienced with antiretroviral therapy.
Nukoolkarn S; Pongthapisith V; Panyim S; Leelamanit W
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1368-72. PubMed ID: 15650431
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
[TBL] [Abstract][Full Text] [Related]
18. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
[TBL] [Abstract][Full Text] [Related]
19. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
[TBL] [Abstract][Full Text] [Related]
20. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
Rosé JR; Babé LM; Craik CS
J Virol; 1995 May; 69(5):2751-8. PubMed ID: 7535864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
